Articles by Petros Grivas, MD, PhD
Dr. Grivas provides perspective of the long-term outcomes from the JAVELIN Bladder 100 trial as pertaining to older patients.
The panel elaborates on what excites them most about the future of UC research, highlighting promising advancements.
The panel considers the evolving role of ctDNA in guiding adjuvant therapy decisions, highlighting IMvigor011 and MODERN.
The panel shares the NIAGARA findings and results from RETAIN-2 on dose-dense MVAC for bladder preservation.
The panel covers 2L treatment options for mUC post-EV/pembro, with emphasis on platinum-based chemo and targeted therapy.
The panel debates patient selection, alternative regimens, and the balance between escalation and de-escalation strategies.
The panel weighs the impact of long-term survival data from the EV-302 trial, with significant improvements in OS.
Neoadjuvant Pembrolizumab and aMVAC for Non-Urothelial MIBC: Does This Combination Improve Outcomes?
Drs. Grivas, Khaki, and Raychaudhuri discuss a phase II trial evaluating pembrolizumab plus aMVAC for non-UC MIBC. 
Four experts weigh in on their survey-based study of sequencing after 1L EV/pembro in the evolving landscape of la/mUC.
In the final part of this roundtable, Drs. Koshkin and Grivas discuss the use of EV/pembro and which patients are eligible.
In part five of this roundtable, the panelists explore the use of ctDNA in the TOMBOLA and IMvigor011 trials.
In the fourth part of this roundtable series, the panelists discuss recent updates on bladder-sparing treatments.
During the final part of this panel, novel ADCs are explored and analyzed for use in different settings.
During the fourth segment of this panel, novel ADCs including HER3, Nectin-4, and BT8009 are analyzed.
In the third part of this panel, the use of HER2 ADCs in bladder cancer is explored.
In the second segment of this panel, the use of sacituzumab govitecan monotherapy and combinations is discussed.
In the first part of this panel, the use and impact of enfortumab vedotin in the bladder cancer landscape is considered.
In part 3 of this roundtable, the NIAGARA trial is discussed, along with cisplatin regimens and the potential of durvalumab.
In the second part of this roundtable, new trials including VOLGA and EV-304 are analyzed.
In part 1, the panelists examine the evolving treatment landscape of MIBC and NMIBC, including discussion on new trials.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.